KALA BIO, Inc. financial data

Symbol
KALA on Nasdaq
Industry
Pharmaceutical Preparations
Location
1167 Massachusetts Avenue, Arlington, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Kala Pharmaceuticals, Inc. (to 6/23/2023)
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 296 % -53.6%
Debt-to-equity 467 % +42%
Return On Equity -389 % -37.6%
Return On Assets -68.7 % -4.12%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.45M shares +129%
Common Stock, Shares, Outstanding 6.09M shares +121%
Entity Public Float 23.9M USD -29.9%
Common Stock, Value, Issued 6K USD +100%
Weighted Average Number of Shares Outstanding, Basic 3.8M shares +56.1%
Weighted Average Number of Shares Outstanding, Diluted 3.8M shares +56.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 5.17M USD -6.95%
General and Administrative Expense 18.3M USD -10.8%
Operating Income (Loss) -41M USD -3.33%
Nonoperating Income (Expense) 2.47M USD +29.4%
Net Income (Loss) Attributable to Parent -38.5M USD +8.74%
Earnings Per Share, Basic -10.2 USD/shares +41.5%
Earnings Per Share, Diluted -1.93 USD/shares +43.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 51.2M USD +0.56%
Assets, Current 52.8M USD -0.14%
Property, Plant and Equipment, Net 749K USD -0.53%
Operating Lease, Right-of-Use Asset 1.69M USD -16.5%
Assets 55.5M USD -0.83%
Accounts Payable, Current 628K USD -31.7%
Employee-related Liabilities, Current 2.39M USD -8.64%
Accrued Liabilities, Current 4.5M USD -28.2%
Liabilities, Current 17M USD +103%
Operating Lease, Liability, Noncurrent 1.43M USD -20.3%
Liabilities 43.2M USD -10.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1K USD
Retained Earnings (Accumulated Deficit) -668M USD -6.12%
Stockholders' Equity Attributable to Parent 12.3M USD +64.3%
Liabilities and Equity 55.5M USD -0.83%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.8M USD -12%
Net Cash Provided by (Used in) Financing Activities 8.44M USD +195%
Net Cash Provided by (Used in) Investing Activities -13K USD +88%
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 6.09M shares +121%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.42M USD +65.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.14M USD -6.76%
Deferred Tax Assets, Valuation Allowance 140M USD +8.37%
Deferred Tax Assets, Gross 140M USD +8.22%
Operating Lease, Liability 1.81M USD -15%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -38.5M USD +8.74%
Property, Plant and Equipment, Gross 2.06M USD +10.7%
Operating Lease, Liability, Current 380K USD +13.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 622K USD +3.49%
Lessee, Operating Lease, Liability, to be Paid, Year One 601K USD +3.44%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 493K USD -34.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 644K USD +3.54%
Deferred Tax Assets, Operating Loss Carryforwards 121M USD +11.2%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 440K USD -31.7%
Operating Lease, Payments 581K USD +186%
Additional Paid in Capital 680M USD +6.8%
Depreciation, Depletion and Amortization 66K USD -14.3%
Share-based Payment Arrangement, Expense 8.39M USD +12.4%
Interest Expense 5.8M USD -13.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%